MyVisionTest News Archive

Displaying news items tagged with PrONTO (More tags »)
SELECT PAGE
First <<  1 2   >> Last

Lucentis
Feb 27, 2011
There is less improvement of vision with as-needed intravitreal Lucentis (ranibizumab) than with monthly injections, according to a new study. Ocular anti-VEGF therapy has presented a major breakthrough in the care of patients with exudative AMD, giving rise to a wide array of therapeutic strategies among retinal specialists, with no consensus...

Full Article


Intravitreal injection
Jan 20, 2011
Ocular anti-VEGF therapy has presented a major breakthrough in the care of patients with exudative AMD, giving rise to a wide array of therapeutic strategies among ophthalmologists, with no consensus on optimal practices. As an alternative to the strict regimen of monthly intravitreal injection used in the protocols of the pivotal ranibizumab...

Full Article


Intravitreal injection
Dec 21, 2009
The MARINA and ANCHOR clinical trials of Lucentis (ranibizumab) therapy for exudative age-related macular degeneration (AMD) followed a fixed dosage regimen and fixed duration of 2 years. Hence, the trials did not provide any information about the “when to stop” endpoint. Because anti-VEGF drugs are angiostatic - they inactivate rather than...

Full Article


Retinal angiomatous proliferation
Nov 26, 2009
Treat and Extend is an effective dosing strategy for the treatment of patients with retinal angiomatous proliferation, according to a new study. Since the first suggestion of a non-monthly dosing regimen in the PrONTO study, many retinal specialists have moved toward dosing individualization, with maintenance therapy provided on an as-needed...

Full Article


Intravitreal injection
Oct 24, 2009
Despite the adoption of non-monthly anti-VEGF dosing schedules by some retinal experts for treatment of exudative age-related macular degeneration, clinical trial evidence to date has not definitively proven that as-needed therapy is either superior or inferior to monthly dosing, according to a speaker at the American Academy of Ophthalmology....

Full Article


Lucentis
Sep 25, 2009
Lucentis (ranibizumab) had a beneficial effect on visual outcome, along with safe and well-tolerated results, in treating neovascular age-related macular degeneration (AMD), according to the SAILOR study. The SAILOR study was a phase IIIb follow-up study to the MARINA and ANCHOR studies to evaluate the long-term safety and efficacy of Lucentis...

Full Article


Intravitreal injection
Sep 19, 2009
The visual outcome of patients undergoing Lucentis (ranibizumab) therapy for exudative age-related macular degeneration (AMD) under an as-needed dosing schedule is related to the number of injections received but not to the resolution of fluid by optical coherence tomography (OCT), according to a new research study. The ANCHOR and MARINA...

Full Article


Lucentis
Sep 18, 2009
The results of Lucentis (ranibizumab) therapy for neovascular age-related macular degeneration (AMD) in a retinal specialty practice located in Paris, France are significantly worse than the results reported from the PrONTO study. The PrONTO study was designed to investigate the possibility of reducing the frequency of treatment with Lucentis...

Full Article


Avastin
Jun 22, 2009
A new study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Avastin (bevacizumab) on an as-needed basis over 2 years finds that 43% of patients experienced a 3-line or more improvement in visual acuity (VA) and an average of 4.9 injections were administered over the 24-month follow-up period. In the...

Full Article


Lucentis
Jun 22, 2009
The PrONTO Study has released results from the second year of follow-up of patients with wet age-related macular degeneration (AMD) that are treated with intravitreal Lucentis (ranibizumab) on an as-needed basis using optical coherence tomography (OCT) data that show as-needed treatment can achieve visual outcomes comparable to monthly Lucentis...

Full Article


SELECT PAGE
First <<  1 2   >> Last
Most Popular
Less - past - More